ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: B-R-Dex or BT-R-Dex treatment markedly suppressed the expression of the oncoprotein BCR-ABL in these tissues compared with PBS, Dex, or CML-mock-Dex treatment (Figs. 5f and 6f).